

Resource Summary Report

Generated by [RRID](#) on Aug 8, 2026

TOX Antibody, anti-human/mouse, APC, REAfinity™

RRID:AB_2751485

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-118-335, RRID:AB_2751485

Antibody Information

URL: http://antibodyregistry.org/AB_2751485

Proper Citation: Miltenyi Biotec Cat# 130-118-335, RRID:AB_2751485

Target Antigen: TOX

Host Organism: human

Clonality: monoclonal

Comments: Antigen distribution: T cells, thymocytes, T helper cells, liver, other
Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-107-785. (RRID:AB_2654225).

Antibody Name: TOX Antibody, anti-human/mouse, APC, REAfinity™

Description: This monoclonal targets TOX

Target Organism: mouse, human

Clone ID: clone REA473

Antibody ID: AB_2751485

Vendor: Miltenyi Biotec

Catalog Number: 130-118-335

Record Creation Time: 20250820T052421+0000

Record Last Update: 20250820T212948+0000

Ratings and Alerts

No rating or validation information has been found for TOX Antibody, anti-human/mouse, APC, REAfinity™.

No alerts have been found for TOX Antibody, anti-human/mouse, APC, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Crain CR, et al. (2026) Expansion of stemlike HIV-specific CD8+ T cells and limited viral epitope diversity characterize durable posttreatment control of HIV. Science translational medicine, 18(846), eaed0042.

Agesta A, et al. (2026) The transcription factor Eomes drives a stemness program in CD4+ T cells that promotes anti-tumor immunity in response to immunotherapy. Immunity, 59(7), 1876.

Scharping NE, et al. (2026) Proteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte function. Cell, 189(10), 2857.

Niu D, et al. (2025) Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors. Cell reports. Medicine, 6(10), 102413.

Coulibaly ASK, et al. (2025) Id2 levels determine the development of effector vs. exhausted tissue-resident memory CD8+ T cells during CNS chronic infection. Cell reports, 44(6), 115861.

Mujal AM, et al. (2025) Splenic TNF- γ signaling potentiates the innate-to-adaptive transition of antiviral NK cells. Immunity, 58(3), 585.

Chen J, et al. (2025) Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. Cancer cell, 43(3), 361.

Bachem A, et al. (2025) Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8+ T cell immunity against melanoma. Immunity, 58(11), 2799.

Ngiow SF, et al. (2024) LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Cell, 187(16), 4336.

Memon D, et al. (2024) Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer cell, 42(2), 209.

Andrews LP, et al. (2024) LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN- γ -dependent anti-tumor immunity. *Cell*, 187(16), 4355.

Tooley K, et al. (2024) Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity. *Cell reports. Medicine*, 5(7), 101640.

Hirsch T, et al. (2024) IRF4 impedes human CD8 T cell function and promotes cell proliferation and PD-1 expression. *Cell reports*, 43(7), 114401.

Blaeschke F, et al. (2023) Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. *Cell*, 186(19), 4216.

Popovi $\acute{c}$ B, et al. (2023) Time-dependent regulation of cytokine production by RNA binding proteins defines T cell effector function. *Cell reports*, 42(5), 112419.

Baxter AE, et al. (2023) The SWI/SNF chromatin remodeling complexes BAF and PBAF differentially regulate epigenetic transitions in exhausted CD8+ T cells. *Immunity*, 56(6), 1320.

Bergaggio E, et al. (2023) ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. *Cancer cell*, 41(12), 2100.

Jung IY, et al. (2023) Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors. *Cell reports. Medicine*, 4(6), 101053.

Beltra JC, et al. (2023) Stat5 opposes the transcription factor Tox and rewires exhausted CD8+ T cells toward durable effector-like states during chronic antigen exposure. *Immunity*, 56(12), 2699.

Kilian M, et al. (2023) MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. *Cancer cell*, 41(2), 235.